medigraphic.com
Colegio de Medicina Interna de México.

2022, Number 5

<< Back Next >>

Med Int Mex 2022; 38 (5)

Characterization of patients with sickle cell anemia in Medellin, Colombia

Martínez-Sánchez LM, Villegas-Alzate JD, Herrera-Almanza L, Correa-Saavedra MA, Gálvez-Cárdenas KM, Hernández-Martínez A, Roldán-Tabares MD, Vergara-Yanez D

Language: Spanish
References: 18
Page: 1012-1018
PDF size: 194.73 Kb.


ABSTRACT

Objective: To characterize patients with a diagnosis of sickle cell anemia in a highly complex health institution in the metropolitan area of Medellin, Colombia.
Materials and Methods: A retrospective, descriptive, observational study done from January 2013 to December 2017 including patients with a diagnosis of sickle cell anemia. For the analysis, relative and absolute frequencies were used for qualitative variables, while average, median, mean and standard deviation were used for quantitative variables with normal distribution and median and interquartile ranges for those with non-normal distribution.
Resultads: Seventy-four patients with sickle cell anemia were included, with a median age at the time of diagnosis of 3 years, male sex predominated with 56.8% (n = 42). Regarding the health regime, 59.5% (n = 44) belonged to the contributory system, followed by the subsidized plan with 25.7% (n = 19). Regarding the clinical manifestations, 66.2% presented a vaso-occlusive events and/or chronic hemolysis.
Conclusiones: Vaso-occlusive events and moderate anemia were predominant in this study, which is of great importance for health professionals, because from these events derive non-infectious and infectious complications of the patients, as well as the hemodynamic requirements when establishing therapeutic management.


REFERENCES

  1. Pinto VM, Balocco M, Quintino S, Forni GL. Sickle cell disease:a review for the internist. Intern Emerg Med 2019; 14(7): 1051-1064. doi:10.1007/s11739-019-02160-x.

  2. Zúñiga C P, Martínez G C, González R LM, et al. Enfermedadde células falciformes: Un diagnóstico para tener presente[Sickle cell disease: A diagnosis to keep in mind]. RevChil Pediatr 2018; 89 (4): 525-529. doi:10.4067/S0370-41062018005000604.

  3. Salinas-Cisneros G, Thein SL. Recent advances in thetreatment of sickle cell disease. Front Physiol 2020; 11:

  4. doi: 10.3389/fphys.2020.00435.4. Alrayyes S, Baghdan D, Haddad RY, Compton AA, et al. Sicklecell disease; An overview of the disease and its systemiceffects. Dis Mon 2018; 64 (6): 283-289. doi: 10.1016/j.disamonth.2017.12.003.

  5. Risoluti R, Caprari P, Gullifa G, Massimi S, Sorrentino F,Maffei L, et al. Innovative screening test for the early detectionof sickle cell anemia. Talanta 2020; 219: 121243.doi: 10.1016/j.talanta.2020.121243.

  6. Thein MS, Igbineweka NE, Thein SL. Sickle cell disease inthe older adult. Pathology 2017; 49 (1): 1-9. doi: 10.1016/j.pathol.2016.10.002.

  7. Tisdale JF, Thein SL, Eaton WA. Treating sickle cell anemia.Science 2020; 367 (6483): 1198-1199. doi: 10.1126/science.aba3827.

  8. Hebbel RP, Belcher JD, Vercellotti GM. The multifacetedrole of ischemia/reperfusion in sickle cell anemia.J Clin Invest 2020; 130 (3): 1062-1072. doi: 10.1172/JCI133639.

  9. Hoppe C, Neumayr L. Sickle cell disease: monitoring,current treatment, and therapeutics under development.Hematol Oncol Clin North Am 2019; 33 (3): 355-371. doi:

  10. 10.1016/j.hoc.2019.01.014.10. Ballas SK, Darbari DS. Review/overview of pain in sicklecell disease. Complement Ther Med 2020; 49: 102327.doi: 10.1016/j.ctim.2020.102327.

  11. Rees DC, Williams TN, Gladwin MT. Sickle-cell disease.Lancet 2010; 376 (9757): 2018-2031. doi:10.1016/S0140-6736(10)61029-X.

  12. Risoluti R, Caprari P, Gullifa G, Massimi S, Sorrentino F,Maffei L, et al. Innovative screening test for the early detectionof sickle cell anemia. Talanta 2020; 219: 121243.doi: 10.1016/j.talanta.2020.121243.

  13. Cesar P, Dhyani A, Schwade LA, Acordi P, Albuquerque C,Nina R, et al. Epidemiological, clinical, and severity characterizationof sickle cell disease in a population from theBrazilian Amazon. Hematol Oncol Stem Cell Ther 2019; 12(4): 204-10. doi 10.1016/j.hemonc.2019.04.002.

  14. Badawy SM, Barrera L, Cai S, Thompson AA. Associationbetween Participants’ characteristics, patient-reportedoutcomes, and clinical outcomes in youth with sicklecell disease. Biomed Res Int 2018; 2018: 8296139. doi:10.1155/2018/8296139.

  15. Zavala G, Viera W, Castillo G, Mejía G, Bustillo P, Fajardo E,et al. Prevalencia de anemia drepanocítica en poblaciónde la comunidad de San Juan, Yoro. Rev Fac Cienc Méd2014; 11 (1): 17-25.

  16. Rosales-Sánchez A, Fu-Carrasco L, López-Urquía R. Perfilclínico y epidemiológico de pacientes con enfermedadde células falciformes atendidos en el bloque maternoinfantil del hospital escuela. Rev Med Post Unah 2001; 6(3): 311-19.

  17. González G, Salmon S. Hidroxiurea en el tratamiento deniños y adolescentes con depranocitosis. Medisan 2012;16 (6): 881-87.

  18. Pila R, Osbert G, Herere R, Tamakloe K. Anemia de célulasfalciformes. Estudio comparativo en Cuba y Santa Lucía.AMC 2002; 6 (Suppl 1): 688-98.




2020     |     www.medigraphic.com